Pipeline

Antengene
RESEARCH FIELD

R&D and Innovation

Candidate Molecule

Target/
Mechanism

Rights

Preclinical

IND

Phase I

Phase II

Phase Ⅲ

NDA

Partner

Candidate Molecule

Target/
Mechanism

Rights

Preclinical

IND

Phase I

Phase II

Phase Ⅲ

NDA

Partner

  • PD-L1
  • Worldwide
  • MSI-H/dMMR advanced cancer (mono, 2L+, ORR, tissue agnostic indication)

  • BTC (combo with chemo vs. chemo, randomized, OS, 1L)

  • Sarcoma (mono, +ipilimumab, ORR, 2L+)

  • NSCLC (combo, 1L)

  • NSCLC (combo, 2L+)

  • Urothelial cancer (mono vs. BSC, 1L maintenance)

  • TMB-H advanced cancer (2L+ mono)

  • Endometrial cancer (combo with lenvatinib, 2L+)

  • HCC (combo with VEGF inhibitor, 2L+)

  • Renal cell carcinoma (combo with VEGF inhibitor, 1L/ 2L+)

  • Multiple indications

  • Alphamab Group
    Simcere Group
    TRACON
  • WT1
  • Great China
  • Multiple indications

  • AML/MPM/OC/MM

  • SELLAS Group
  • GAS6/AXL
  • Great China
  • NSCLC/OC/RCC/UC

  • OC/RCC/UC

  • Aravive
  • COX-2
  • China
  • Post-surgical dental pain/cancer pain

  • Haihe Biopharma Group
  • EP-4
  • China
  • Cancer pain / osteoarthritis

  • Haihe Biopharma Group
  • FGFR1/2/3
  • Worldwide
  • Solid tumors / BTC / UC

  • Haihe Biopharma Group & SIMM
  • TKI prodrug
  • Worldwide
  • HCC / RCC / PC

  • CD47
  • Great China
  • Multiple indications

  • Multiple indications

  • ImmuneOncia
  • CD3+PD-L1
  • Greater China + Worldwide Priority Transfer right
  • Multiple indications

  • Y-Biologics
  • WT1
  • Greater China
  • Multiple indications

  • SELLAS Group
  • Sema4D
  • Worldwide
  • Multiple indications

  • KRAS
  • Worldwide
  • Multiple indications

  1. Envafolimab
  2. 3D189
  3. 3D229
  4. 3D1001
  5. 3D1002
  6. 3D185
  7. 3D011
  8. 3D197
  9. 3D057
  10. 3D059
  11. 3D060
  12. 3D062